Crescita Therapeutics Inc - ESG Rating & Company Profile powered by AI
This report of Crescita Therapeutics Inc employs data from across the internet and also from available filings by Crescita Therapeutics Inc. The ESG score includes 17 UN Sustainable Development Goals including: 'Gender Equality', 'Reduced Inequalities' and 'Peace, Justice & Strong Institutions'. Browse to the end of this page for potential risks for Crescita Therapeutics Inc based on sector, geography and size.
Crescita Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 5.3.
7.1
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
217 | Takara Bio Inc | 7.2 | High |
217 | Ultragenyx Pharmaceutical Inc | 7.2 | High |
224 | Crescita Therapeutics Inc | 7.1 | High |
224 | Celularity Inc | 7.1 | High |
224 | Bilcare Ltd | 7.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Crescita Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does Crescita Therapeutics Inc disclose current and historical energy intensity?
Does Crescita Therapeutics Inc report the average age of the workforce?
Does Crescita Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does Crescita Therapeutics Inc disclose its ethnicity pay gap?
Does Crescita Therapeutics Inc disclose cybersecurity risks?
Does Crescita Therapeutics Inc offer flexible work?
Does Crescita Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Crescita Therapeutics Inc disclose the number of employees in R&D functions?
Does Crescita Therapeutics Inc conduct supply chain audits?
Does Crescita Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Crescita Therapeutics Inc conduct 360 degree staff reviews?
Does Crescita Therapeutics Inc disclose the individual responsible for D&I?
Does Crescita Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Crescita Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does Crescita Therapeutics Inc disclose water use targets?
Does Crescita Therapeutics Inc have careers partnerships with academic institutions?
Did Crescita Therapeutics Inc have a product recall in the last two years?
Does Crescita Therapeutics Inc disclose incidents of discrimination?
Does Crescita Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has Crescita Therapeutics Inc issued a profit warning in the past 24 months?
Does Crescita Therapeutics Inc disclose parental leave metrics?
Does Crescita Therapeutics Inc disclose climate scenario or pathway analysis?
Does Crescita Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Crescita Therapeutics Inc disclose the pay ratio of women to men?
Does Crescita Therapeutics Inc support suppliers with sustainability related research and development?
Does Crescita Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Crescita Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Crescita Therapeutics Inc involved in embryonic stem cell research?
Does Crescita Therapeutics Inc disclose GHG and Air Emissions intensity?
Does Crescita Therapeutics Inc disclose its waste policy?
Does Crescita Therapeutics Inc report according to TCFD requirements?
Does Crescita Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Crescita Therapeutics Inc disclose energy use targets?
Does Crescita Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Crescita Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Crescita Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.